Galderma Receives U.S. FDA Approval For Nemluvio® (Nemolizumab) For Patients With Moderate-To-Severe Atopic Dermatitis -....
(MENAFN- AETOSWire) (BUSINESS WIRE )--Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic …